Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Octreotid (ausgeschlossen Dafo. DFL,PLS,TRS), ATC H01CB02 f. d. Z. 1.7.26-30.6.28 (zzgl. V.-Option 1x12 Mon)

Section 130a (8) SGB V allows health insurance funds and pharmaceutical companies to conclude framework rebate contracts for medicines to be dispensed at the expense of the statutory health insurance funds. With regard to the relevant legal provisions for the award of public contracts, the DAK-Gesundheit regularly conducts substance-related, formal tendering procedures in accordance with the regulations of Part 4 of the GWB. For the medicines to be specified by the bidder in more detail in Annex 2 to the contract, relating to the aforementioned active substance Octreotid (excluding the dosage forms DFL, PLS, TRS), ATC H01CB02, the DAK-Gesundheit intends to conclude medicine rebate contracts with as many interested pharmaceutical companies as possible until the entry into force of new medicine rebate contracts. A rebate contract in accordance with the approval model for the aforementioned active substance will come into force for the first time on 01.07.2026 and will end on 30.06.2028 (plus extension option 1x12 months). It will end automatically with the entry into force of the exclusive contract, regardless.